Evidence map›Paper›PMID 23755307›Full record

ArticlePloS one2013

Decreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells.

Qunyan Jin, Guangming Liu, Phillip P Domeier, Wei Ding, Kathleen M Mulder

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qunyan JinDepartment of Biochemistry and Molecular Biology, Penn State Hershey College of Medicine, Hershey, Pennsylvania, United States of America.
Guangming Liu
Phillip P Domeier
Wei Ding
Kathleen M Mulder
Penn State Milton S. Hershey Medical Center · US

Funding

Mechanisms of TGF-Beta Production in Human Cancer CellsR01CA090765 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MULDER, KATHLEEN M · 2001 to 2011
$3.1M
Role of TGFBeta in Microtubule DynamicsR01CA092889 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MULDER, KATHLEEN M · 2001 to 2011
$2.9M
NCI NIH HHS CA090765NCI NIH HHS CA092889NCI NIH HHS R01 CA090765NCI NIH HHS R01 CA092889
6 · The paper itself

Abstract

We have previously described a novel modulator of the actin cytoskeleton that also regulates Ras and mitogen-activated protein kinase activities in TGFβ-sensitive epithelial cells. Here we examined the functional role of this signaling regulatory protein (km23-1) in mediating the migration, invasion, and tumor growth of human colorectal carcinoma (CRC) cells. We show that small interfering RNA (siRNA) depletion of km23-1 in human CRC cells inhibited constitutive extracellular signal-regulated kinase (ERK) activation, as well as pro-invasive ERK effector functions that include phosphorylation of Elk-1, constitutive regulation of c-Fos-DNA binding, TGFβ1 promoter transactivation, and TGFβ1 secretion. In addition, knockdown of km23-1 reduced the paracrine effects of CRC cell-secreted factors in conditioned medium and in fibroblast co-cultures. Moreover, km23-1 depletion in human CRC cells reduced cell migration and invasion, as well as expression of the ERK-regulated, metastasis-associated scaffold protein Ezrin. Finally, km23-1 inhibition significantly suppressed tumor formation in vivo. Thus, our results implicate km23-1 as a novel anti-metastasis target for human colon carcinoma cells, capable of decreasing tumor growth and invasion via a mechanism involving suppression of various pro-migratory features of CRC. These include a reduction in ERK signaling, diminished TGFβ1 production, decreased expression of the plasma membrane-cytoskeletal linker Ezrin, as well as attenuation of the paracrine effects of colon carcinoma-secreted factors on fibroblast migration and mitogenesis. As such, km23-1 inhibitors may represent a viable therapeutic strategy for interfering with colon cancer progression and invasion.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell Line, TumorCell MovementCollagenColorectal NeoplasmsCytoplasmic DyneinsCytoskeletal ProteinsDiffusion Chambers, CultureDrug Combinationsets-Domain Protein Elk-1Extracellular Signal-Regulated MAP KinasesEzrinFemaleGenetic VectorsHumansCollagenCytoplasmic DyneinsCytoskeletal ProteinsDrug CombinationsDYNLRB1 protein, humanets-Domain Protein Elk-1Extracellular Signal-Regulated MAP KinasesEzrinLamininmatrigelProteoglycansProto-Oncogene Proteins c-fosRNA, Small InterferingTransforming Growth Factor beta1

Identifiers

PMID23755307
PMCPMC3670870
OpenAlexW2092922783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.